Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (34)

I-06Elisabeth Rouits

Population pharmacokinetic model for Debio 1143, a novel antagonist of IAPs in cancer treatment

Wednesday 10:05-11:40

I-10Maria Luisa Sardu

Tumour Growth Inhibition In Preclinical Animal Studies: Steady-State Analysis Of Biomarker-Driven Models.

Wednesday 10:05-11:40

I-11Emilie Schindler

PKPD-Modeling of VEGF, sVEGFR-1, sVEGFR-2, sVEGFR-3 and tumor size following axitinib treatment in metastatic renal cell carcinoma (mRCC) patients

Wednesday 10:05-11:40

I-36Iñaki F. Trocóniz

Modelling and simulation applied to personalised medicine

Wednesday 10:05-11:40

I-41Georgia Valsami

Population exchangeability in Bayesian dose individualization of oral Busulfan

Wednesday 10:05-11:40

I-43Coen van Hasselt

Design and analysis of studies investigating the pharmacokinetics of anti-cancer agents during pregnancy

Wednesday 10:05-11:40

I-52Camille Vong

Semi-mechanistic PKPD model of thrombocytopenia characterizing the effect of a new histone deacetylase inhibitor (HDACi) in development, in co-administration with doxorubicin.

Wednesday 10:05-11:40

I-58Mélanie Wilbaux

A drug-independent model predicting Progression-Free Survival to support early drug development in recurrent ovarian cancer

Wednesday 10:05-11:40

II-09

drugCARD: a database of anti-cancer treatment regimens and drug combinations

Wednesday 14:50-16:20

II-24Pascal Girard

Tumor size model and survival analysis of cetuximab and various cytotoxics in patients treated for metastatic colorectal cancer

Wednesday 14:50-16:20

II-26Timothy Goggin

Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies.

Wednesday 14:50-16:20

II-31Verena Gotta

Simulation-based systematic review of imatinib population pharmacokinetics and PK-PD relationships in chronic myeloid leukemia (CML) patients

Wednesday 14:50-16:20

II-38Emilie Hénin

Optimization of sorafenib dosing regimen using the concept of utility

Wednesday 14:50-16:20

III-01Stefanie Kraff

Excel®-Based Tools for Pharmacokinetically Guided Dose Adjustment of Paclitaxel and Docetaxel

Thursday 10:05-11:35

III-10

Modeling Targeted Therapies in Oncology: Incorporation of Cell-cycle into a Tumor Growth Inhibition Model

Thursday 10:05-11:35

III-18Hyeong-Seok Lim

Pharmacokinetics of S-1, an Oral 5-Fluorouracil Agent in Patients with Gastric Surgery

Thursday 10:05-11:35

III-25Paolo Magni

A PK-PD model of tumor growth after administration of an anti-angiogenic agent given alone or in combination therapies in xenograft mice

Thursday 10:05-11:35

III-26Mathilde Marchand

Population Pharmacokinetics and Exposure-Response Analyses to Support Dose Selection of Daratumumab in Multiple Myeloma Patients

Thursday 10:05-11:35

III-27Eleonora Marostica

Population Pharmacokinetic Model of Ibrutinib, a BTK Inhibitor for the Treatment of B-cell malignancies

Thursday 10:05-11:35

III-31

Modeling tumor dynamics and overall survival in patients with low-grade gliomas treated with temozolomide.

Thursday 10:05-11:35

III-32Litaty Céphanoée Mbatchi

A PK-PGx study of irinotecan: influence of genetic polymorphisms of xenoreceptors CAR (NR1I3) and PXR (NR1I2) on PK parameters

Thursday 10:05-11:35

III-34Christophe Meille

Modeling of Erlotinib Effect on Cell Growth Measured by in vitro Impedance-based Real-Time Cell Analysis

Thursday 10:05-11:35

III-35

Characterizing the dose-efficacy relationship for anti-cancer drugs using longitudinal solid tumor modeling

Thursday 10:05-11:35

III-55Ignacio Ortega

Application of allometric techniques to predict F10503LO1 PK parameters in human

Thursday 10:05-11:35

III-58Zinnia Parra-Guillen

Population semi-mechanistic modelling of tumour response elicited by Immune-stimulatory based therapeutics in mice

Thursday 10:05-11:35

III-64Angelica Quartino

Evaluation of Tumor Size Metrics to Predict Survival in Advanced Gastric Cancer

Thursday 10:05-11:35

IV-13

Modeling Erlotinib and Gefitinib in Vitro Penetration through Multiple Layers of Epidermoid and Colorectal Human Carcinoma Cells

Thursday 14:55-16:20

IV-28Brigitte Brockhaus

Semi-mechanistic model-based drug development of EMD 525797 (DI17E6), a novel anti-αv integrin monoclonal antibody

Thursday 14:55-16:20

IV-31Núria Buil Bruna

Modelling LDH dynamics to assess clinical response as an alternative to tumour size in SCLC patients

Thursday 14:55-16:20

IV-37Quentin Chalret du Rieu

Hematological toxicity modelling of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor, in patients suffering from solid tumors or lymphoma: influence of the disease-progression on the drug-induced thrombocytopenia.

Thursday 14:55-16:20

IV-40Christophe Chassagnole

Virtual Tumour Clinical: Literature example

Thursday 14:55-16:20

IV-53Damien Cronier

PK/PD relationship of the monoclonal anti-BAFF antibody tabalumab in combination with bortezomib in patients with previously treated multiple myeloma: comparison of serum M-protein and serum Free Light Chains as predictor of Progression Free Survival

Thursday 14:55-16:20

IV-55Elyes Dahmane

Population Pharmacokinetics of Tamoxifen and three of its metabolites in Breast Cancer patients

Thursday 14:55-16:20

IV-57Camila De Almeida

Modelling Irinotecan PK, efficacy and toxicities pre-clinically

Thursday 14:55-16:20